OncLive Staff

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in February 2026 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in lung cancer, renal cell carcinoma, prostate cancer, head and neck cancer, and multiple myeloma.

The FDA has granted accelerated approval to zongertinib in HER2 TKD–mutated NSCLC, full approval to an encorafenib combination in BRAF V600E+ mCRC, and more.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The top 5 OncLive TV videos of the week cover insights in genitourinary cancers, hematologic malignancies, colorectal cancer, and sarcoma.

The FDA approved a frontline acalabrutinib regimen in CLL/SLL and a simplified dosing schedule for Rybrevant Faspro in EGFR+ NSCLC and will review NDAs in PCNSL and breast cancer.

The top 5 OncLive TV videos of the week cover insights in kidney cancer, myeloproliferative neoplasms, breast cancer, systemic mastocytosis, and pancreatic cancer.

The FDA approves pembrolizumab regimen in select ovarian cancer, the agency clears Optune Pax for pancreatic cancer, and more this week.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in January 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in acute lymphoblastic leukemia, breast cancer, urothelial cancer, ovarian cancer, and follicular lymphoma.

The FDA granted priority review to Dato-DXd in triple-negative breast cancer, accepted an NDA for zanzalintinib plus atezolizumab in mCRC, and more.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

The FDA has approved Darzalex Faspro plus VRd for select multiple myeloma and several applications are under regulatory review in lung and GI cancers.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, breast cancer, and colorectal cancer.

The FDA issued a CRL for tabelecleucel in EBV+ PTLD, a BLA was submitted for an ivonescimab regimen in EGFR-mutated NSCLC, and more.

The top 5 OncLive TV videos of the week cover insights in lung cancer, bladder cancer, gastrointestinal cancer, and multiple myeloma.

A rusfertide NDA for polycythemia vera has been submitted to the FDA, a tafasitamab combination boosts PFS over R-CHOP in DLBCL, and more.

Here is your Q1 2026 preview spotlighting 5 FDA decisions to watch, including upcoming PDUFAs for tabelecleucel, pembrolizumab, and more.

The top 5 OncLive TV videos of the week cover insights in leukemia, lung cancer, multiple myeloma, indolent systemic mastocytosis, and pancreatic cancer.

The FDA cleared narsoplimab for TA-TMA, an NDA seeking approval of bezuclastinib in nonadvanced systemic mastocytosis has been submitted, and more.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in December 2025 spanning tumor types.

The top 5 OncLive TV videos of the week cover insights in ALL, breast cancer, lung cancer, and pancreatic cancer.

The FDA approved subcutaneous mosunetuzumab for relapsed/refractory follicular lymphoma and granted a pair of breakthrough therapy designations.

The top 5 OncLive TV videos of the week cover insights in myeloma, AML, Ph-positive ALL, pediatric low-grade glioma, and nonadvanced systemic mastocytosis.

The FDA approved T-DXd plus pertuzumab in HER2+ breast cancer, subcutaneous amivantamab in EGFR+ NSCLC, and rucaparib in BRCA-mutated mCRPC.

The top 5 OncLive TV videos of the week cover insights in acute myeloid leukemia, follicular lymphoma, multiple myeloma, and Ph+ B-ALL.

The FDA approved Akeega for use in BRCA2+ mCSPC, granted priority review to the sBLA for nivolumab plus AVD in classical Hodgkin lymphoma, and more.

The top 5 OncLive TV videos of the week cover insights in ovarian cancer, lung cancer, urothelial cancer, and prostate cancer.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.